US GI drugs panel review for Debiopharm's Sanvar
This article was originally published in Scrip
Executive Summary
Debiopharm's oesophageal bleeding treatment Sanvar (vapreotide acetate immediate release) will be reviewed by the US FDA's gastrointestinal drugs advisory panel on May 19th.